Hepatic Glucose Production, Ureagenesis, and Lipolysis Quantified using the Perfused Mouse Liver Model
October 6th, 2023
2.9K views
Here, we present a robust method for in situ perfusion of the mouse liver to study the acute and direct regulation of liver metabolism without disturbing the hepatic architecture but in the absence of extra-hepatic factors.
Overview
This study presents a robust method for in situ perfusion of the mouse liver, allowing researchers to investigate liver metabolism regulation without disrupting hepatic architecture. The technique enables minute-to-minute quantification of metabolic processes, enhancing translational relevance in understanding liver diseases.
Key Study Components
Area of Science
- Neuroscience
- Metabolism
- Liver physiology
Background
- The liver plays a crucial role in metabolic regulation.
- Understanding liver responses to nutrient and hormonal changes is vital for addressing liver diseases.
- Acute and non-transcriptional regulation of metabolism is significant in liver function.
- Existing models may not accurately reflect in vivo conditions.
Purpose of Study
- To develop a method for studying liver metabolism in situ.
- To assess the effects of hormones like glucagon on liver function.
- To enhance the understanding of dysmetabolic conditions in liver diseases.
Methods Used
- In situ perfusion of mouse liver.
- Minute-to-minute quantification of metabolic processes.
- Characterization of signaling cascades related to glucagon.
- Comparison of responses within the same mouse liver for increased control.
Main Results
- The perfused liver method maintains intact hepatic architecture.
- Viability of the liver is sustained for at least three hours.
- Novel signaling pathways related to glucagon were identified.
- The technique allows for detailed analysis of metabolic responses.
Conclusions
- The in situ perfusion method is a significant advancement for liver research.
- It provides insights into the acute regulation of liver metabolism.
- This approach may improve understanding of liver diseases such as fatty liver disease and diabetes.
Frequently Asked Questions
What is the significance of in situ perfusion?
In situ perfusion allows for the study of liver metabolism without disrupting its architecture, providing more accurate results.
How long can the liver remain viable during perfusion?
The liver can remain viable for at least three hours during the perfusion process.
What metabolic processes can be quantified using this method?
The method allows for the quantification of various metabolic processes, including the release of metabolites in real-time.
Why is glucagon important in this study?
Glucagon plays a vital role in liver metabolism and understanding its signaling pathways can help address dysmetabolic conditions.
How does this method compare to traditional in vitro models?
This method maintains the liver's architecture and viability, offering a more relevant model compared to traditional in vitro systems.
What diseases are being targeted with this research?
The research targets liver diseases, particularly fatty liver disease and diabetes, by understanding metabolic regulation.
Executive Industry Relevance
The perfused mouse liver model enables high-resolution quantification of hepatic glucose production, ureagenesis, and lipolysis under controlled conditions, supporting mechanistic de-risking in metabolic disease research. By preserving intact hepatic architecture and isolating liver-specific responses, this system enhances predictive confidence for target validation and translational biomarker development. Its capacity for within-sample controls and time-resolved measurements positions it as a critical tool at the discovery-to-preclinical interface for metabolic and endocrine portfolio programs.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables direct interrogation of hepatic metabolic pathways in response to hormones and nutrients.
- Supports functional validation of targets implicated in glucose, urea, and lipid metabolism.
- Facilitates mechanistic de-risking by isolating liver-specific effects from systemic influences.
- Provides quantitative, time-resolved data to inform predictive models and triage targets.
Screening & Assay Development
- Delivers validated, physiologically relevant readouts for compound screening in hepatic metabolism.
- Supports assay reproducibility through internal controls and stable liver viability for up to three hours.
- Enables standardization of metabolic output measurements for cross-study comparability.
- Prepares robust biological systems for downstream pharmacological evaluation.
Translational & Preclinical Research
- Aligns metabolic outputs with disease-relevant endpoints for fatty liver disease and diabetes models.
- Bridges discovery findings to preclinical validation by maintaining physiological context.
- Supports risk-adjusted advancement decisions through quantitative biomarker alignment.
- Enhances translational continuity by modeling acute and non-transcriptional regulation.
Pipeline & Workflow Integration
This model integrates into the discovery continuum from early mechanistic studies through lead identification and preclinical validation for metabolic and endocrine indications.
- Discovery Biology: Enables hypothesis testing of hepatic metabolic regulation and pathway mapping.
- Screening: Provides reproducible, quantitative outputs for compound and hormone evaluation.
- Analytics: Supports minute-to-minute measurement of glucose, urea, and fatty acid release for comparative analysis.
- Translational Research: Connects acute metabolic responses to disease-relevant phenotypes and biomarker strategies.
- Enterprise Reuse: Offers a reusable platform for diverse metabolic and signaling studies across programs.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence and reduces mechanistic ambiguity in hepatic target validation.
- Operational Value: Delivers standardized, reproducible, and scalable metabolic assays.
- Strategic Value: Improves go/no-go decisions and capital efficiency by enabling robust biological de-risking.
- Portfolio Impact: Supports risk-adjusted prioritization and advancement of metabolic disease assets.
Implementation Considerations
- Requires expertise in microsurgical techniques and hepatic physiology.
- Needs specialized perfusion instrumentation and analytical platforms for metabolic readouts.
- Demands rigorous cross-team standardization for data comparability and reproducibility.
- Adaptation may be needed for different mouse strains or disease models.
- Viability limited to three hours; throughput and scalability should be planned accordingly.
Biopharma FAQs
Why does null hypothesis testing matter for hepatic glucagon response?
Null hypothesis testing enables objective evaluation of whether glucagon infusion significantly alters hepatic glucose and fatty acid release, supporting robust target validation and reducing false positives in metabolic pathway analysis.
How does independent variable isolation fit the perfused liver workflow?
By perfusing the liver in situ and controlling hormone or nutrient infusions, the model isolates hepatic responses from extra-hepatic influences, clarifying direct mechanistic effects for discovery-stage decision making.
What do quantitative glucose and urea measurements enable in this model?
Minute-to-minute quantification of glucose and urea output allows teams to compare baseline and stimulated states, enabling precise assessment of metabolic pathway activation and compound efficacy.
Why are replication requirements critical for cross-functional liver studies?
Replication within the same liver and across experiments ensures that observed metabolic changes are robust and reproducible, facilitating reliable data sharing and collaboration between discovery and translational teams.
What statistical analysis capabilities are required before implementing metabolic output assays?
Teams must apply statistical methods to distinguish true metabolic responses from baseline variability, ensuring that observed changes in glucose, urea, or fatty acid release meet significance thresholds for advancement decisions.
